deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024
deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification in sepsis and other acute infections, today announces the launch of its UllCORE diagnostic system, currently in development, with its first application in the early detection of sepsis. Read more
Peptomyc Appoints Selwyn Ho to its Board of Directors
Peptomyc S.L., a clinical stage company specialized in the development of protein therapeutics targeting the MYC oncoprotein for cancer treatment, today announced the appointment of Dr. Selwyn Ho, MB, BS, to its Board of Directors. Read more
MYC targeting by OMO-103 in solid tumors: a phase 1 trial
Peptomyc presents results of their Ph1 study of OMO-103 in advanced solid tumours. OMO-103 is an inhibitor for MYC, one of the most wanted, long-considered, undruggable oncogenes. The trial has established the safety, tolerability and pharmacokinetic profile of OMO-103, advising on Ph2 design and identifying soluble factors with the potential as pharmacodynamic and predictive response […]
Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial
Peptomyc is proud to announce that the results of the MYCure clinical trial have just been published in Nature Medicine (https://www.nature.com/articles/s41591-024-02805-1), demonstrating the unique potential of our lead first-in-class MYC inhibitor, OMO-103, to treat multiple oncological indications. Peptomyc takes pride in pioneering the blockade of a most-wanted target in cancer, and we believe this encouraging […]
binx health Enters into National Distribution Agreement with Cardinal Health to Increase Access to the CLIA-waived, FDA-cleared binx io
binx health, a healthcare technology and diagnostics company focused on expanding Sexually Transmitted Infection testing at the Point-of-Care, announced a national distribution agreement with Cardinal Health to expand access to care with the CLIA-waived, FDA-cleared binx io to improve the timely diagnosis of chlamydia (CT) and gonorrhea (NG). Read more
binx health Expands Nationwide Distribution of the binx io Molecular Point-of-Care Platform
binx health announced today it has entered into a non-exclusive national distribution agreement with Fisher Healthcare, a part of Thermo Fisher Scientific, to expand the rollout of the CLIA-waived, FDA-cleared binx io, which will increase access to care and improve the timely diagnosis of chlamydia (CT) and gonorrhea (NG). Read more
InBrain Neuroelectronics wins FDA breakthrough nod for intelligent network modulation system
InBrain Neuroelectronics announced today that it received FDA breakthrough device designation for its intelligent network modulation system. Read more
Aliath Bioventures appoints Dr Philippe Monteyne and announces additional hires to further strengthen its Life Sciences Impact business
Aliath Bioventures, the healthcare impact investment platform of AltamarCAM Partners, appoints Philippe Monteyne, MD, PhD as a new Partner to reinforce the company’s healthcare investment team. As of 16th November 2023, Philippe Monteyne will join the team responsible for Alta Life Sciences Spain I FCR and the newly launched, ACP Aliath Bioventures II FCR (ABV […]
New appointment
Delighted to have Pamela Klein join the board of one of the companies of Alta Life Sciences Spain I FCR. Read more
